Thank you for your interest, we’ll get in touch with you shortly!
Du använder Internet Explorer, en webbläsare som slutade utvecklas 6 november 2013, för över 9 år sedan. Den 31 januari 2020 upphörde även alla säkerhetsuppdateringar vilket innebär att webbläsaren, förutom funktionella och utseendemässiga brister även kan utgöra en säkerhetsrisk. Du rekommenderas starkt att uppgradera till en modernare webbläsare, t ex Google Chrome, Mozilla Firefox eller Microsoft Edge. Tala med din systemadministratör.
i-Balans has solved a global problem by being the first company to develop a method and system for patient assessment that is built around WHO’s guidelines for patient-assessment for care and support centres, ICF. i-Balans offers a web-based care-centre support measurement tool used for patient assessment, scheduling, HR and care-centre planning, optimization, analysis and reporting.
Edwoak Life Science’s vision is to create a more healthy and sustainable society through innovation and digitization! Welfare actors today have major challenges with reduced financial resources and recruitment of personnel. Because of this, the collaborative work between the actors needs to be made more efficient. Our digital planning and communication tool is there to address this and make a real difference to people’s health and society’s sustainability.
Early screening is a major issue with alzheimer disease. Indeed, currently patients often get diagnosed too late, once they have cognitive impairment. As a result, treatments are less efficient and cannot repair the damage already caused by the disease. At Mantis Photonics, we have developed a patented hyperspectral camera that can detect biomarkers of alzheimer in the retina. This will be used as a non-invasive early detection tool for the screening of the population.
Cardiovascular diseases (CD) are the leading cause of global deaths, with misdiagnoses in pre-specialist settings all too common. Non-specialists often struggle with ECG interpretation, which can lead to life-threatening consequences. HATO is a medical technology company utilizing AI to analyze ECG recordings in real-time and provide accurate diagnoses. Our software utilizes deep learning and an innovative 3D heart model, enabling healthcare professionals to quick and accurate decisions.
Bio-Me is transforming microbiome analysis by making it possible to analyze hundreds of samples in less than a day, with high resolution and reproducibility and at an affordable cost. Combined with an exclusive biobank and extensive patient database, Bio-Me’s Precision Microbiome Profiling platform (PMP™) enables the development of clinical tests that will improve health and well-being worldwide.
Musculoskeletal problems affect 1 in 2 people, with 100M people in the EU with chronic pain and 40% without a diagnosis. Qinematic is a movement intelligence company that develops and licenses Moovment(R) software to help people move well so they can move more. It is used by health professionals to quickly record and analyse human movement in 3D, and by consumers to track their progress using 2D video from a mobile phone. Corrective exercises and results are shared in a web application.
PeckiiLess is a Sweden-based company that has created a nano-sensor that can detect blood glucose levels through human exhalation to an extremely accurate level. Hundreds of millions of people, most diabetics, around the world rely on accurate glucose monitoring to lead a healthy life. Current methods are invasive can be painful, are expensive, wasteful and not universally available. PeckiiLess can improve the lives of these people.
Revolutionizing how patients take their medicine. Everyone deserves to live a good life, but for many that’s only possible with just the right medication. We want to help here by starting a revolution combining traditional pharmaceuticals, individualized dosing and digital health solutions.
Diabetes Services is building a human-centric digital ecosystem of data using services for diabetes- and lifestyle management for better health and quality of life.
There is a strong demand for imaging of retinal structures on a cellular level, such as photoreceptors and capillaries, in order to improve diagnosis of retinal disease and prevent vision loss. Profundus offers 10 times higher resolution than conventional retinal imaging instruments and 50 times higher corrected imaging area than competing concepts. Profundus aim to provide researchers and clinicians with a tool that can visualize currently subclinical changes of retinal disease.